HealthLeaders Media May 16, 2022
Laura Beerman

One Michigan plan is bringing predictive power to patient drug treatment.

As the social determinants of health grab healthcare’s spotlight, the genetic determinants of health provide precision medicine benefits that one health plan is banking on.

Blue Care Network, a subsidiary of Blue Cross Blue Shield of Michigan (BCBS-MI), has launched Blue Cross Personalized Medicine, the state’s first pharmacogenomics (PGx) program. PGx is a subset of genomics that uses genetic testing to help predict an individual patient’s response to specific drug therapies.

“Our first priority with the Blue Cross Personalized Medicine program is to ensure that a physician is able to provide the right medication, at the right dose, as early in the process as possible,” stated a BCBS-MI press...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Equity/SDOH, Healthcare System, Insurance, Patient / Consumer, Payer, Pharma / Biotech, Precision Medicine, Provider
What the Medicaid unwinding means for plans, providers, and more
What Impact is AI Having on the Collection and Analysis of RWE?
WebMD Ignite launches new member engagement platform for payers
How the payer workforce will evolve, per 11 executives
22 state AGs: UnitedHealth's Change Healthcare hack response inadequate

Share This Article